253 related articles for article (PubMed ID: 37046255)
1. Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China.
Xu W; Zhang Z; Li D; Dai W; Pan C; Guo M; Zhao Y; Cui X
BMC Health Serv Res; 2023 Apr; 23(1):361. PubMed ID: 37046255
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
Chen M; Zhang X; Xiong Y; Xu G
Int Urol Nephrol; 2023 Mar; 55(3):641-651. PubMed ID: 36161550
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
5. Rituximab or cyclosporine a for the treatment of membranous nephropathy: Economic evaluation of the MENTOR trial.
Kadatz M; Klarenbach S; So H; Fervenza FC; Cattran DC; Barbour SJ
Nephrol Dial Transplant; 2024 Apr; ():. PubMed ID: 38621719
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis.
Dai P; Xie W; Yu X; Sun J; Wang S; Kawuki J
Int Immunopharmacol; 2021 May; 94():107376. PubMed ID: 33582591
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China.
Zeng L; Chen H; Xiang H; Zeng M; Zhou M; Tan C; Liu H; Chen G
Front Pharmacol; 2023; 14():1309930. PubMed ID: 38259264
[No Abstract] [Full Text] [Related]
8. Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model.
Hamilton P; Kanigicherla D; Venning M; Brenchley P; Meads D
Nephrol Dial Transplant; 2018 Dec; 33(12):2145-2155. PubMed ID: 29617884
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis for
Huang X; Huang X; Lin S; Luo S; Dong L; Lin D; Huang Y; Xie C; Nian D; Xu X; Weng X
BMJ Open; 2023 Mar; 13(3):e068943. PubMed ID: 36972963
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R.
Santos AS; Andrade JP; Freitas DA; Gonçalves ÉSD; Borges DL; Carvalho LMA; Noronha KVMS; Andrade MV
Value Health Reg Issues; 2023 Jul; 36():10-17. PubMed ID: 36966699
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
Kong W; Yang X; Shu Y; Li S; Song B; Yang K
Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
16. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
[TBL] [Abstract][Full Text] [Related]
17. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China.
Cao W; Yu Y; Qiu Y; Liu L; Zhang H; Shi L; Xiao Y; Jia L; Zhang R; Wang X
BMC Health Serv Res; 2022 Dec; 22(1):1580. PubMed ID: 36567324
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.
Lin W; Li HY; Lin S; Zhou T
Drug Des Devel Ther; 2019; 13():2179-2186. PubMed ID: 31308629
[TBL] [Abstract][Full Text] [Related]
20. A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis.
Li YC; Huang J; Li X; Zhao SM
Nefrologia (Engl Ed); 2019; 39(3):269-276. PubMed ID: 30755327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
